DT&CRO Co Ltd
383930
Company Profile
Business description
DT&CRO Co Ltd conducts a series of consigned research, from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional foods, cosmetics and medical devices, to analysis, bioactivity, clinical trials, and licensing consulting. provided as a service.
Contact
28, Baengnyeong-ro 20beon-gil
2nd, 3rd, 4th floor, Na-dong
Cheoin-gu, Gyeonggi-do (Yubang-dong)
Yongin-si17042
KORT: +82 313222400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
345
Stocks News & Analysis
stocks
Global tensions drive profitability for ASX energy provider
Supply disruptions turbocharge refining profits and lift earnings forecasts for ASX energy share.
stocks
ASX energy share undervalued ahead of earnings
Pricing strength outweighs temporary production headwinds.
stocks
Tesla: Reported China divestiture plan could clear path for SpaceX merger
Media report says Tesla is exploring divestiture plans to ease regulatory approval of a Tesla-SpaceX merger.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,311.90 | 125.80 | 1.37% |
| CAC 40 | 8,631.62 | 17.80 | 0.21% |
| DAX 40 | 26,185.07 | 183.76 | 0.71% |
| Dow JONES (US) | 53,178.41 | 693.38 | 1.32% |
| FTSE 100 | 10,903.93 | 46.23 | 0.43% |
| HKSE | 25,852.92 | 156.48 | -0.60% |
| NASDAQ | 25,913.90 | 540.04 | 2.13% |
| Nikkei 225 | 63,957.53 | 202.63 | 0.32% |
| NZX 50 Index | 13,903.46 | 128.53 | 0.93% |
| S&P 500 | 7,600.50 | 110.78 | 1.48% |
| S&P/ASX 200 | 9,145.80 | 122.80 | 1.36% |
| SSE Composite Index | 3,822.28 | 12.62 | 0.33% |